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Abstract 
Sugammadex, a γ-cyclodextrin that encapsulates selectively steroidal neuromuscular blocking 
agents, such as rocuronium or vecuronium, has changed the face of clinical neuromuscular 
pharmacology. Sugammadex allows a rapid reversal of muscle paralysis. Sugammadex appears to be 
safe and well tolerated. Its blood-brain barrier penetration is poor (< 3% in rats), and thus no 
relevant central nervous toxicity is expected. However the blood brain barrier permeability can be 
altered under different conditions (i.e. neurodegenerative diseases, trauma, ischemia, infections, or 
immature nervous system).  
Using MTT, confocal microscopy, caspase-3 activity, cholesterol quantification and Western-blot 
we determine toxicity of Sugammadex in neurons in primary culture. Here we show that clinically 
relevant sugammadex concentrations cause apoptotic/necrosis neuron death in primary cultures. 
Studies on the underlying mechanism revealed that sugammadex-induced activation of mito-
chondria-dependent apoptosis associates with depletion of neuronal cholesterol levels. Fur-
thermore SUG increase CytC, AIF, Smac/Diablo and CASP-3 protein expression in cells in culture. 
Potential association of SUG-induced alteration in cholesterol homeostasis with oxidative stress 
and apoptosis activation occurs. Furthermore, resistance/sensitivity to oxidative stress differs 
between neuronal cell types. 
Key words: Sugammadex, apoptosis, CytC, AIF, Smac/Diablo and CASP-3. 
1. Introduction 
Sugammadex (SUG), a γ-cyclodextrin with a 
doughnut-like molecular structure containing a lipo-
philic core and a hydrophilic periphery, is the first in a 
new (and revolutionary) class of selective binding 
reversal agents that terminates neuromuscular 
blockade (NMB) with different NMB drugs such as 
rocuronium (ROC) or vecuronium (VEC) [1]. The 
negative charges of the external chains maintain the 
cavity open and the core, with Van Der Waals forces, 
thermodynamic bonds and hydrophobic interactions, 
creates a 1:1 ratio complex with very tight bonds be-
tween the NMB drug and SUG [2]. SUG, depending 
on the dose, can reverse a moderate or deep NMB 
without muscle weakness [3]. 
A Cochrane systematic review including 18 
randomized controlled trials (with a total of 1321 pa-
tients) on the efficacy and safety of SUG concluded 
that it was more effective than placebo (no medica-
tion) or neostigmine in reversing muscle relaxation 
caused by NMB during surgery and is relatively safe. 
Serious complications occurred in less than 1% of the 








for SUG included cough, dry mouth, temperature 
changes, parasomia, paresthesia, movement during 
surgery, mild erythemia, abdominal discomfort, 
tachycardia, bradycardia, dizziness, increased creati-
nine phosphokinase, and increased B2 microglobinu-
ria [3]. Pooled preclinical safety data obtained from 
the US FDA briefing document [5]; and the European 
Medicines Agency scientific document (EMEA)[6] 
reveal no special hazard for humans based on con-
ventional studies of safety pharmacology, repeated 
dose toxicity, genotoxicity and toxicity to reproduc-
tion, local tolerance or compatibility with blood. Po-
tential kidney and lung toxicity of cyclodextrins, if 
large repeated doses are administered, must be also 
taken into account [7]. Besides, available information 
regarding SUG on special conditions/population, 
including renal impairment, elderly patients, obese 
patients, and pediatric population is really limited [5, 
6, 8]. 
Owing to its singular architecture, charge, and 
high molecular weight (2178.01), SUG exhibits a very 
low transfer across the blood-brain barrier (BBB) and 
the placenta [9]. This particularity apparently pre-
cludes any significant SUG-derived toxicity in the 
central nervous system (CNS). Nevertheless, different 
clinical conditions imply moderate or severe altera-
tions of the BBB integrity, i.e. Alzheimer [10], Parkin-
son [11] or multiple sclerosis [12] disease-associated 
neurodegeneration, traumatic brain/spinal cord in-
jury [13], ischemia [14], meningitis [15], or immature 
nervous system [16]. Under these clinical conditions, 
SUG may cross the BBB in specific areas. This report 
suggests, for the first time, potential SUG-induced 
neuronal toxicity. 
2. Material and Methods 
2.1. Materials 
Dulbecco’s modified Eagle’s medium (DMEM) 
and fetal bovine serum (FBS) was obtained from 
Gibco life technology (Gibco Invitrogen Corporation, 
Barcelona, Spain). SUG was from Merck Millipore 
products, Sharp & Dohme (Madrid, Spain). Appro-
priate concentration of SUG was tested in figure 1 and 
selected a standard concentration of 75 µg/ml during 
24 h for further experiments. Western blot enhanced 
chemo-luminescent detection system (ECL) was from 
Amersham Bioscience (Amersham Biosciences, Bar-
celona, Spain). Monoclonal anti-glial fibrillary acidic 
protein (anti-GFAP) antibody (1:500) was from Sig-
ma-Aldrich Biotech (Madrid, Spain). Monoclonal an-
ti-MAP-2 protein (anti-MAP-2) antibody (1:500) and 
monoclonal anti-cytochrome C protein (anti-CytC) 
antibody (1:500) were from Santa Cruz Biotechnology 
(Barcelona, Spain). Anti-apoptosis-inducing factor 
(anti-AIF) (1:500) and anti-Smac/Diablo (1:500) were 
from Sigma-Aldrich Biotech. (Barcelona, Spain). All 
other reagents were of analytical or culture grade pu-
rity. 
2.2. Primary cultures 
Primary cultures of cortical neurons were pre-
pared from the cerebral cortex (5 female rats to obtain 
the fetuses) of 14-15-day old rat fetuses. Briefly the 
cerebral cortex, obtained under toxin-free sterile con-
ditions, was dissected and dissociated mechanically 
by pipetting 10 times with DMEM (10 ml for the cor-
tex obtained from 12-14 fetuses). The cell suspension 
was filtered through a nylon mesh with a pore size of 
90 μm. Cell suspension was plated (5 x 104 cells/cm2) 
on poly-lysine-coated dishes. After attachment of the 
cells (1 h), the plating medium was changed to DMEM 
pH 7.4, supplemented with 10% fetal bovine serum 
(FBS), 10 mM HEPES, 40 mM NaHCO3, 100 units/ml 
penicillin, and 100 mg/ml streptomycin. Primary 
cultures of cortical astrocytes were prepared from the 
cerebral cortex (5 female rats to obtain the fetuses) of 
21-day old rat fetuses. Briefly the cerebral cortex, ob-
tained under toxin-free sterile conditions, was dis-
sected and dissociated mechanically by pipetting 10 
times with DMEM (10 ml for the cortex obtained from 
12-14 fetuses). The cell suspension was filtered 
through a nylon mesh with a pore size of 90 μm. Cell 
suspension was plated (5 x 104 cells/cm2) with 20% 
FBS, 10 mM HEPES, 40 mM NaHCO3, 100 units/ml 
penicillin, and 100 mg/ml streptomycin. After 4 days, 
the plating medium was changed with medium pre-
pared such as above. At seven days of culture 20% 
was changed to 10% FBS. 
Cultures were grown in a humidified atmos-
phere of 5% CO2 and 95% O2, at 37oC, for 3 days, and 
then exposed to cytosine β-D arabinofuranoside (10 
μM) for 24 h to prevent proliferation of no neuronal 
cells. Possible contamination by astrocytes was as-
sessed by immune-fluorescence using monoclonal 
anti-glial fibrillary acidic protein (GFAP) (astrocytes 
marker: Sigma-Aldrich. 1:500) antibody (clone G-A-5) 
and polyclonal anti-microtubule-associated protein 2 
(MAP-2) (neuronal marker: Sigma-Aldrich. 1:500). 
Under these conditions approx. 99% ± 3 of all cultured 
cells were neurons [17]. Cell viability, assessed by the 
MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetraz
olium bromide] assay [18], was normalized relative to 
control cells whose viability was taken as 100% when 
treated for the indicated periods with the corre-
sponding vehicles. Cell viability in controls, as meas-
ured by the release of lactate dehydrogenase activity 
to the extracellular medium, was always >90%. All 
animal work was performed according to minimize 
animals suffering and to reduce the number of ani-




mals used following the local ethics committees (Eth-
ics Committee for Animal Research of the University 
of Valencia) based on the local guidelines (Spanish 
law 32/2007). 
2.3. Immunofluorescence and confocal mi-
croscopy 
 Neurons monolayers growing on 16-mm glass 
coverslips were used for immune-fluorescence studies 
following the procedure described by Valles et al. [17]. 
Monoclonal anti-MAP-2 and anti-GFAP antibodies 
(Sigma-Aldrich) were used to see the purity of cul-
ture. Incubation was performed at 37ºC for 60 min. 
After washing several times with phosphate-buffered 
saline (PBS), neurons were then incubated with sec-
ondary antibodies. When necessary, the nuclei were 
stained (0.5 µg/ml) with Hoechst 33342 dye (Molec-
ular Probes) for 5 min. In other experiments, astro-
cytes were incubated with mitotracker and Hoechst 
and neurons were incubated simultaneously with 
Annexin V, Hoechst and Rhodamine to see apoptosis 
and necrosis.  
2.4. Cell death analysis 
Apoptotic and necrotic cell death induced by 
SUG were distinguished by using fluorescence mi-
croscopy [19]. Briefly, isolated cells were incubated 
with Hoescht 33342 (10 mM; which stains all nuclei) 
and Rhodamine (10 µg/ml; to stain mitochondria in 
living cells), for 3 min, and analyzed using a Diaphot 
300 fluorescence microscope (Nikon, Tokyo, Japan) 
with excitation at 360 nm. Nuclei of viable, necrotic, 
for apoptotic cells were observed as blue round nu-
clei, pink round nuclei, and fragmented blue or pink 
nuclei, respectively. About 1500 cells were counted 
each time. DNA strand breaks in apoptotic cells were 
assayed by using a direct TUNEL labeling assay 
(Boehringer, Mannheim, Germany) and fluorescence 
microscopy following manufacturer’s methodology. 
2.5. Western-blots 
Attached cells (neurons in primary culture) was 
collected and were harvested with ice-cold buffer 
(0.125 M Tris-HCl, pH 6.8, 2% SDS, 19% glycerol, 1 
mM phenylmethylsulfonyl fluoride, 1μg/ml leupep-
tin, 1μg/ml aprotinin, and 1μg/ml pepstatin), pH 7.4, 
disrupted by repeated cycles of freezing and thawing, 
and boiled for 5 min at 90º. Cell extracts were ho-
mogenized and centrifuged (10000 x g for 10 min at 
4ºC). The resulting supernatant was used for west-
ern-blot analysis. Protein concentration was deter-
mined using a modified Lowry method [20]. Proteins 
were separated by SDS-PAGE gels and transferred to 
nitrocellulose membranes using standard techniques. 
Membranes were blocked with 5% dried milk in TBS 
containing 0.05% Tween-20 and then incubated with 
the corresponding antibodies following manufactur-
er’s recommendations. The blots were washed three 
times with phosphate-buffered saline containing 0.2% 
Tween 20 for 15 min and then incubated for 1 h with a 
secondary horseradish peroxidase-linked anti-rabbit 
or anti-mouse IgG antibody (Cell Signaling Technol-
ogies, Barcelona, Spain). ECL (Pharmacia biotech-
nology, San Francisco, CA) was used for developing. 
Auto-radiographic signals were assessed using a 
Bio-Rad scanning densitometer. 
2.6. TUNEL assay 
Apoptotic cells were assessed by measuring 
DNA fragmentation in a standard TUNEL assay fol-
lowing the instructions with the kit. In brief, cells 
were permeabilized with 0.1% Triton X-100 for 2 min 
on ice, reacted with TdT enzyme, and stained with 
FITC-dUTP for 1 h at 37°C in dark. The 
TUNEL-positive cells were imaged under a fluores-
cent microscope and the cells with green fluorescence 
were defined as apoptotic cells. 
2.7. Caspase 3 activity assay 
This activity was measured in cytosolic fractions 
(see below) by using a highly sensitive colorimetric 
substrate, N-acetyl-Asp-Glu-Val-Asp p-nitroanilide 
(Ac-DEVD-pNA) following manufacturer’s instruc-
tions (CalBiochem, La Jolla, CA). Enzyme activity was 
calculated, using manufacturer’s formulae, as 
pmol/min.  
2.8. Sub-cellular fractionation and cholesterol 
quantification. 
Cultured cortical neurons underwent fractiona-
tion to segregate cytosol and membrane fractions as 
previously described [21, 22]. Briefly, cells in the su-
pernatant collect by centrifugation and attached cells 
scraped in 5 mm EDTA in PBS were pelleted by cen-
trifugation for 10 min at 1000 x g at 4°C. Pellets were 
re-suspended in 200 μl of fractionation buffer (0.25 m 
sucrose, 1 mM Mg chloride, 2 mM EGTA, and 25 mM 
HEPES, pH 7.4) and lysed by three cycles of flash 
freezing in liquid nitrogen. Lysates were then centri-
fuged at 100000 × g for 30 min at 4oC. Supernatants 
(cytosol fraction) were separated and the pellet 
(membrane fraction) was dissolved again in 200 μl of 
fractionation buffer containing 5% Triton X-100 and 
briefly sonicated. Whole-cell lysates were obtained by 
harvesting or homogenizing the samples in 
sub-cellular fractionation buffer containing 2.5% Tri-
ton X-100, followed by brief sonication. 
Neurons were cultured, as indicated above, with 
or without increasing amounts of soluble cholesterol 
(see Results) and/or SUG. Whole cell lysates and 




sub-cellular fractions were lyophilized using 
freeze-drying equipment from SP Scientific (Gardiner, 
NY). Lipids were extracted and cholesterol was de-
termined using cholesterol oxidase as previously de-
scribed [23]. 
2.9. Statistical significance 
Statistical analyses were performed using t-test 
(Student’s t test) and also a one way ANOVA was 
performed with the program GraphPad Prism, with a 
p < 0.05 being considered significant. 
3. Results 
3.1. Sugammadex causes neuronal cell death 
Based on the results displayed in Figure 1, we 
selected a standard concentration of 75 µg/ml of SUG 
for further experiments. Also using im-
mune-fluorescence technique with Anexine V (apop-
tosis) and Rhodamine (necrosis), we detected an in-
crease in apoptosis and necrosis after SUG addition. 
In the experiments displayed as Table 1, we found no 
significant differences when the sum of dead cells 
(calculated along the culture time) and viable cells 
obtained in the presence or in the absence of sugam-
madex was compared (not shown). However, the total 
number of dead neurons was much higher in the 
presence of the γ-cyclodextrin (Table 1), which means 
that neuronal death is the predominant effect caused 
by sugammadex. Most dying cells (90%) displayed 
apoptotic features and only a small percentage was 
identified as necrotic (Table 1). The percentage of 
apoptotic cells obtained by using Hoechst 33342 and 
propidium iodide (Table 1) or the TUNEL technique 
(not shown) was similar. During the 48 h period in the 
presence of the γ-cyclodextrin, almost all nonviable 
cells (94.7 + 3.9 %) lost their attachment to the flasks 
and were progressively recovered in the culture me-
dium. Looking for different pro-apoptotic molecular 
signals (using Western-blot technique), we demon-
strated in figure 2 increase protein expression in CytC, 
AIF and Smac/Diablo after SUG addition compared 
with control cells. Also higher activity of CASP-3 ac-
tivity was noted comparing SUG with control samples 
(Figure 2).  
 
Fig 1. (A) Neuronal cell death induced by sugammadex. Time- and concentration-dependent neurotoxicity of SUG was determined by the MTT assay (*p 
< 0.01). ● (37.5 µg SUG/ml), ○ (75 µg SUG/ml), and □ (150 µg SUG/ml). Data are means ± SD for 5 independent experiments. *p < 0.01 comparing SUG 
vs controls (no additions). ANOVA (two way) was used when needed. (B) Optic microscopic image of cultured neurons incubated in the absence or in the 
presence of SUG (75 µg/ml, 24 h). The % of viable cells in control cultures was always > 95%. (C) Immunofluorescence of neurons in primary culture with 
Hoechst, Annexin V and Rhodamine was used. Astrocytes marked with Hoechst and mitotracker also are shown.  





Fig 2. Cholesterol prevents the increase in pro-apoptotic molecular signals induced by Sugammadex. SUG (75 µg/ml) was present in the culture medium 
for 24 h. CytC, AIF, and Smac/Diablo (western blots) and CASP-3 activity were analyzed as indicated under Materials and Methods. Results of quantitative 
analysis of immunoblots are means ± SD (error bars) (n=5) expressed as relative changes in arbitrary densitometry units (ADU) normalized against an 
internal standard (α-tubulin). *p < 0.01 comparing all conditions vs controls (no additions); +p < 0.01 comparing cholesterol + SUG vs SUG. 
 
3.2. Sugammadex-induced activation of 
apoptosis is linked to an alteration of cellular 
cholesterol homeostasis 
To further investigate the underlying mecha-
nisms responsible of the SUG-induced apoptosis ac-
tivation, we evaluated if this γ-cyclodextrin could 
cause alterations in neuronal cholesterol levels and 
whether this could be linked to apoptosis. As shown 
in Table 2, sub-cellular fractionation revealed that 
SUG indeed decreased membrane-associated, cyto-
solic, and mitochondrial cholesterol levels. Moreover, 
as shown in Figure 2, cholesterol enrichment pre-
vented the release of different pro-apoptotic molecu-
lar signals (including CytC, AIF, Smac/Diablo, or 
CASP-3 activity) caused by SUG. Thus, indicating a 
relationship between alteration of neuronal choles-
terol homeostasis and apoptosis activation induced by 
SUG addition to neuronal cells. 
 
Table 1. Type of neuronal cell death induced by sugam-
madex. 
Parameter No addition SUG 
10-4 x number of death cells/ml 2.1 ± 0.7 8.3 ± 2.3* 
Necrotic cells (%) 46.6 ± 7.5 12.3 ± 4.4* 








Table 2. Effect of sugammadex on the cellular content of Cholesterol in neurons, astrocytes, endothelial cells, and leu-
kocytes. 
 Cholesterol (µg/mg protein) MTT 
(% control)  Whole cell Plasma membrane 
 - SUG +SUG -SUG +SUG -SUG +SUG 
Neurons 30.3 ± 3.7 18.5 ± 2.7* 67.4 ± 5.9 35.1 ± 4.7* 100 ± 2 65 ± 7* 
Astrocytes 51.7 ± 8.2 40.1 ± 5.3 215.6 ± 26.5 177.4 ± 10.2* 100 ± 8 92 ± 10 
Endoth. cells 42.4 ± 3.9 31.7 ± 3.9* 137.3 ± 19.2 116.7 ± 8.7* 100 ± 3 99 ± 12 
Leukocytes 29.6 ± 4.4 20.1 ± 3.5* 176.6 ± 15.2 139.3 ± 9.5* 100 ± 9 97 ± 13 
 
Table 3. Effect of plasma cholesterol-enrichment on sugammadex-induced neuron cell death. 
Treatment Plasma Membrane Cholesterol (µg/mg protein) MTT (% Control) 
None 62.2 ± 3 100 ± 3 
SUG 36.6 ± 5.1* 63 ± 6* 
Cholesterol 83.7 ± 7.9* 102 ± 2 
SUG + Cholesterol 60.5 ± 6.9 97 ± 3 
 
4. Discussion 
NMB drugs are currently used during surgery to 
facilitate muscle relaxation for endotracheal intuba-
tion and artificial ventilation, ensure patient immo-
bility, and easier surgical access to body cavities [24].  
The main advantage of SUG is reversal of NMB 
without relying on inhibition of acetylcholinesterase. 
The amino-steroid molecule bound within SUG's 
lipophilic core is rendered unavailable to bind to the 
acetylcholine receptor at the neuromuscular junction 
[25]. This avoids the autonomic instability produced 
by anti-cholinesterase drugs such as neostigmine, and 
thus antimuscarinic agents such as atropine do not 
need to be co-administered. Moreover, when a fast 
onset and short duration of muscle relaxant is re-
quired, there has been little choice previously apart 
from the use of suxamethonium. Nevertheless, sux-
amethonium is not ideal since it has some undesirable 
side effects, such as anaphylaxis, increasing serum 
potassium levels and different cardiovascular re-
sponses. Since, in high doses, ROC has a reasonably 
rapid onset and now can be reversed with SUG, it can 
potentially be used instead [26].  
The present results indicate potential neuronal 
toxicity at clinically relevant doses of SUG. Never-
theless, as stated in the Introduction, these harmful 
effects should be limited to conditions associated with 
moderate or severe alterations of the BBB integrity. It 
is in this specific context where our findings may 
represent a warning, particularly when relatively high 
doses of this γ-cyclodextrin are required for the rapid 
reversal of NMB. SUG, which does not bind to plasma 
proteins or erythrocytes, distributes into the extracel-
lular water of the body, being its distribution volume 
in adults of approximately 11-14 l [6, 26]. Single-dose 
administration of SUG 16, 20, or 32 mg/kg in combi-
nation with ROC 1.2 mg/kg or VEC 0.1 mg/kg was 
well tolerated in healthy volunteers with no clinical 
evidence of residual NMB, thus concluding that these 
combinations can safely be administered simultane-
ously [27]. Nevertheless, because SUG forms a 1:1 
complex with steroidal NMB drugs, most of the SUG 
molecules administered remain free in the extracellu-
lar water. As shown in Figure 1.A, SUG decreases 
neuronal cell viability in a concentration- and 
time-dependent fashion. Pharmacokinetic studies in 
healthy volunteers showed that after simultaneous 
i.v. administration of SUG (16 mg/kg) and ROC (1.2 
mg/kg) or VEC (0.1 mg/kg), the peak plasma con-
centration of the unbound γ-cyclodextrin was of 70-80 
mg/ml [27]. 
SUG causes cell death, predominantly by apop-
tosis, in cultured neurons (Figure 1, Table 1). Apopto-
sis induction associates with an alteration in neuronal 
cholesterol homeostasis (Table 2). Interestingly, it has 
been shown in A431 cancer cells that cholesterol de-
pletion using methyl-β-cyclodextrin causes apoptosis 
[28]; and in human keratinocytes that disruption of 
lipid rafts by cholesterol-depleting compounds (me-
thyl-β-cyclodextrin, filipin III, cholesterol oxidase, or 
mevastatin) leads to a spontaneous clustering of Fas 
in the non-raft compartment of the plasma membrane, 
formation of Fas-FADD complexes, activation of 
caspase-8, and apoptosis [29]. In fact, neuronal death 
caused by inhibition of intracellular cholesterol traf-
ficking has been shown to be caspase dependent and 
associated with activation of the mitochondrial 
apoptosis pathway [30]. Cholesterol is an abundant 
component of plasma membranes of eukaryotic cells 
and is an essential regulator of membrane fluidity, 
permeability, receptor function, and ion channel ac-




tivity [31]. In fact maintenance of its cellular homeo-
stasis is needed to support cell proliferation and sur-
vival [32]. The distribution of cholesterol in the 
membranes is not uniform and its content is particu-
larly high in the submicroscopic areas also enriched in 
gangliosides and sphingolipids. These micro-domains 
known as lipid rafts, act as molecular platforms that 
spatially organize membrane receptor molecules [33]. 
β-cyclodextrin and carboxymethyl-β-cyclodextrin 
induced caspase-dependent apoptotic cell death in 
human keratinocytes on depletion of membrane cho-
lesterol; whereas α-cyclodextrin, γ-cyclodextrin, and 
2-hydroxypropyl-β-cyclodextrin were not apoptotic 
to this type of cell [34]. Moreover, it is reported that 
cholesterol depletion by methyl-β-cyclodextrine 
blocks cholera toxin transport from endosomes to the 
Golgi apparatus in hippocampal neurons [35]; and 
that enrichment of the neuronal plasma membrane 
with cholesterol protects cortical neurons from apop-
tosis induced by soluble oligomers of the Aβ(1-40) 
peptide [36]. The present report shows for the first 
time that a γ-cyclodextrin can cause neuronal damage, 
and that this effect associates with cholesterol deple-
tion, and that it can be prevented by preloading the 
neurons with cholesterol (Figure 2).  
Some reports support indeed the idea that cho-
lesterol may actually be good for the brain. Consistent 
with this, for instance, maintenance of physiological 
levels of cellular cholesterol appears to decrease the 
neuronal death (reactive oxygen species-associated) 
caused by prion peptides through regulation of p53, 
P-p38 and P-ERK protein levels [37]. Oxidative stress 
plays an important role in neurodegenerative diseas-
es, and recent results show that elevated cellular cho-
lesterol may prevent oxidative stress in different 
neurodegenerative diseases including Alzheimer’s 
disease [38]. Moreover, adaptation of neuronal cells to 
chronic oxidative stress is associated with cholesterol 
accumulation and altered sphingolipid homeostasis 
and lysosomal function [39]. 
Cell stress-associated mitochondrial CytC re-
lease is largely caspase independent, where release of 
Smac/Diablo is a caspase-catalysed event that occurs 
downstream of CytC release. Furthermore, the litera-
ture suggests that apoptosis-associated CytC and 
Smac/Diablo release from mitochondria do not occur 
via the same mechanism. Smac/Diablo export from 
mitochondria into the cytosol is provoked by cyto-
toxic drugs and DNA damage, as well as by ligation 
of the CD95 death receptor [30]. Figure 2 demonstrate 
a higher Smac/Diablo protein expression after SUG 
addiction compared with control samples, showing a 
cell death caused by inhibition of intracellular cho-
lesterol trafficking caspase dependent and associated 
with activation of the mitochondrial apoptosis path-
way. Furthermore, reduction of Smac/Diablo and 
CytC after SUG + Cholesterol was detected compared 
with SUG sample. Other authors have demonstrated 
an increase in Smac/Diablo apoptosis pathway, 
probably by inhibition of bone marrow B-cell devel-
opment and thymic T cell differentiation and de-
creasing splenic T cells, such as has been published by 
Huang and collaborators [30]. 
Nevertheless cholesterol accumulation may be a 
double edge sword since, as other reports suggest, 
excessive accumulation of cholesterol in mitochondria 
may be a key step in promoting e.g. Alzheimer dis-
ease progression [40]. In this scenario U18666A, a 
cholesterol transport-inhibiting agent, leads to high 
intracellular cholesterol accumulation in primary cor-
tical neurons, activation of caspases and calpains, 
hyperphosphorylation of tau, and apoptosis [41].  
The potential association of SUG-induced altera-
tion in cholesterol homeostasis with oxidative stress 
and apoptosis activation, the fact that re-
sistance/sensitivity to oxidative stress may likely dif-
fer between brain regions and neuronal cell types, 
potential neurons-astrocytes interactions, as well as 
modulation by pathological mechanisms such as in-
flammation, all represent new research windows that 
deserve further studies. 
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